Session I

Hodgkin Lymphoma

Primary refractory/early relapse: a world with different opportunities
C.H. Moskowitz
Elderly patient: from frontline to R/R
A.M. Evens
Finally CAR-T?
C.A. Ramos
Session II

DLBCL (excluded CAR-T)

Genomics
R. Dalla Favera
Frontline treatments in DLBCL: the actual scenario and the ongoing trials
G.S. Nowakowski
News from the RWD on polaBR, tafasitamab-lenalidomide and loncastuximab tesirine in R/R patients and their next step
B.D. Cheson
Bispecifics and beyond
C. Thieblemont
Session III

Few pearls on PTCL/CTCL

PDX models in T-cell lymphoma
G.A. Inghirami
STOP CHOP! How to build a new frontline treatment
O.A. O’Connor
New agents and new pathways: the chemo-free era?
E. Marchi
New therapeutic approaches for advanced CTCL: is it realistic?
J.J. Scarisbrick
Session IV

Miscellanea

News on therapeutical approaches in Wandenstrom’s macroglobulinemia
S.P. Treon
Advances in the frontline treatment of mantle cell lymphoma
M.I. Jerkeman
Update on bispecifics in the treatment of indolent lymphoma
E.L. Budde
Lecture

Validation of the Advanced-stage HL International Prognostication Index (A-HIPI): report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium
A.M. Evens
Lecture

How I treat plasmoblastic lymphoma
J.J. Castillo
Session V

CAR-T in non-Hodgkin Lymphoma

Update in DLBCL from third line (clinical trials and RWD)
S.J. Schuster
Update in DLBCL from second line (clinical trials and RWD)
J.S. Abramson
ZUMA 12 and beyond
S.S. Neelapu
Update in MCL (clinical trials and RWD)
M. Wang
CAR-T in PTCL
P.M. Maciocia
Other products and new generation of CAR-T
S.J. Schuster
Privacy Policy | Cookie Policy